Research is being conducted on integrative mendelian randomization approaches to identify therapeutic targets for various immune-mediated diseases. Studies are using techniques such as proteogenomic analyses, single-cell transcriptome-wide mendelian randomization, and multi-omics mendelian randomization to investigate diseases including ischemic stroke, cancers, atopic dermatitis, and multiple sclerosis. These analyses aim to prioritize potential drug targets and identify causal insights across different omics layers.